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Abstract
Introduction. Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma 
(PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can 
be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical 
CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients 
with CSTPTC in the Silesian region. 
Material and methods. All the available clinical and histopathological data for 149 patients with CSTPTC from 
the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) 
men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center 
between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20). 
Results. In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher 
expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). 
CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node 
involvement (pN), or distant metastases (pM).
Conclusions. Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the 
carcinoma progression of CSTPTC. The association between lower CK19 expression and patients’ unfavorable 
postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis. (Folia Histochemica 
et Cytobiologica 2016, Vol. 54, No. 4, 193–201)
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Introduction
Thyroid carcinoma is the most common endocrine 
malignant tumor, and in recent decades, its incidence 
has considerably increased [1–3]. This type of malig-
nancy occurs twice as often in Caucasian people as 
in Black, but the highest rates occur among patients 
from Southeast Asia [4]. The incidence of this tumor 
in Poland is also increasing [5]. It accounts for 2.6% of 
all oncological diseases in women and 0.5% in men [5]. 
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The majority of thyroid carcinomas arise from 
follicular cells and, although patients generally have 
good survival rates and postsurgical prognosis, some-
times these thyroid tumors take a very aggressive 
course. For this reason, the main goal of recent stud-
ies has been to improve the accuracy of the current 
diagnostic tools so as to identify those tumors with 
aggressive features [1–3]. Many clinical and patho-
logical factors are associated with poor prognosis 
of thyroid carcinoma [6]. The most frequently used 
are age, gender, distant metastases, lymph node in-
volvement, histopathological subtypes, greater size of 
primary tumor, and multifocality [6]. 
In turn, papillary thyroid carcinoma (PTC) is the 
most common thyroid malignancy, accounting for 
80–90% of all thyroid malignant tumors [7–9]. As 
with thyroid carcinomas in general, the prognosis of 
PTC is favorable, and the ten-year survival rate of the 
classical subtype of PTC (CSTPTC) is over 90% [9]. 
CSTPTCs may also be very aggressive, as demonstrat-
ed by the recurrence of the disease. Environmental, 
genetic, immunological, and hormonal factors are 
considered possible pathomechanisms for thyroid 
malignancy recurrence [10, 11]. 
Besides hematoxylin and eosin staining for evaluat-
ing thyroid tumor morphology, immunohistochemical 
(IHC) methods have been widely used [1, 2]. IHC mark-
ers are of two types: those related to proteins present 
in normal thyrocytes (such as thyroglobulin and thyroid 
transcription factor-1) and those related to proteins in 
pathological thyrocytes (such as cytokeratin-19, thyroid 
peroxidase, and Hector Battifora mesothelial epitope-1) 
[12]. Cytokeratins (CKs) are a family of intermediate 
filaments of epithelial cells. In cytoplasm, CK filaments 
form a specific network connecting the cell membrane 
with the nucleus, serving to position and anchor the nu-
cleus within the cell. Apart from their mechanical role as 
components of the cytoskeleton, CKs also participate in 
cellular processes such as mitosis, the postmitotic period, 
cell movement, differentiation, and apoptosis [13]. 
There are two types of cytokeratins: the acidic cy-
tokeratins and the neutral and basic cytokeratins [14]. 
Both include specific subsets of cytokeratins, which 
are numbered from 1 to 20. The acidic type is repre-
sented by cytokeratins 9–20, and the neutral and basic 
type are numbered from 1 to 8 [14]. 
The expression of some cytokeratins is often tis-
sue-specific or organ-specific, and these differences 
also apply to various malignancies [14]. CK profiles 
have thus been widely determined by immunohisto-
chemistry for the diagnosis and characterization of 
malignant tumors [15].
Among the acidic cytokeratins is cytokeratin 19 
(CK19), which is composed of approximately 400 ami-
no acids and has a molecular weight of 40 kDa. The 
human gene encoding CK19 is localized on chromo-
some 17q21-22 [16, 17]. Some authors have suggested 
that, during cell differentiation, CK19 can be regarded 
as a universal cytokeratin, because it can form dimers 
with any cytokeratin from the second group [18]. Sol-
uble fragments of CK19 can be detected with ELISA 
using the CYFRA 21-1 assay [19]. CK19 is observed 
in the ductal epithelium of the pancreas and bile duct, 
and very often is considered a biomarker of hepatocel-
lular carcinoma, PTC, squamous cell carcinoma, and 
large bowel adenocarcinoma [20–23]. Jain et al. [24] 
pointed to CK19 as an independent prognostic factor 
for neuroendocrine tumors of the pancreas. High 
levels of expression of CK19 in thyroid carcinoma 
have been described not only in humans, but also in 
animals [25]. Ciaputa et al. described the strong posi-
tive immunoreactivity of CK19 in a vesicular-compact 
type of thyroid carcinoma in dogs [25]. 
Positive CK19 staining has been observed in 
papillary thyroid cancer (PTC), and is recognized as 
a reliable tumor marker of PTC [12, 26, 27]. In par-
ticular, IHC staining of CK19 has been found to be an 
accurate marker in diagnosing malignancy in thyroid 
nodules through the immunoreactivity of CK19 in 
cells obtained during the fine needle aspiration biopsy 
procedure [28]. 
The most common subtypes of PTC include the 
classic (CSTPTC), follicular, and tall-cell variants [29]. 
However, many other uncommon variants of PTC 
have also been described, including oncocytic and 
columnar cell variants, diffuse sclerosing and solid 
forms, clear cell and cribriform-morular variant [29]. 
In 2010, Asioli et al. [30] described another very 
rare variant of PTC which they called “PTC with 
prominent hobnail features”. However, the useful-
ness of CK19 as a postsurgical prognostic factor of 
CSTPTC in various populations is so far unknown or 
controversial [31, 32]. The aim of our study was thus 
to investigate relationships between the intensity of 
CK19 expression at the time of diagnosis of CSTPTC 
and its clinical and pathological characteristics — and 
particularly the postsurgical outcomes in patients in 
the Silesian region of Poland. 
Material and methods
The study was approved by the Bioethics Committee of Wro-
claw Medical University, Poland (number: KB-419/2015).
Patients. The study was performed on 149 archival paraffin 
blocks of 149 histologically diagnosed CSTPTC cases. All 
patients had been treated surgically at the Department and 
Clinic of General, Gastroenterological, and Endocrine Sur-
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gery at Wroclaw Medical University, Poland. At the time of 
diagnosis and treatment, the majority of patients were in the 
very initial stages of the disease (132 patients, 88.59% of the 
total, in stage I or II); however, there were 15 (10.06%) and 
2 (1.34%) patients in stages III and IV, respectively. All in-
dividuals underwent the standard total thyroidectomy with 
central lymphadenectomy. The surgical tissue specimens were 
fixed in 10% buffered formalin and diagnosed histopatho-
logically at the Department of Pathomorphology, Wroclaw 
Medical University, Poland. All available clinical and patho-
logical data, along with the postoperative specimens from the 
149 patients, were retrospectively examined (Table 1). The 
group consisted of 135 (90.6%) women and 14 (9.4%) men. 
The mean age was 52.3 ± 15.0 years. The time of the follow 
up was 24 to 90 months (mean and SD: 47 ± 20 months). All 
patients (100%) have survived the follow up period.
Histopathological examination and analysis of IHC. H&E 
sections were evaluated by two independent pathologists 
to confirm the diagnosis and to assess whether the CSPTC 
was unifocal or multifocal. All cases represented classical 
forms of papillary thyroid carcinoma without any histolo-
gical variants. The microscopic diagnosis of PTC was based 
on nuclear features: enlargement, overlapping, irregularity 
of nuclear contours, grooves, clearing, a ground-glass ap-
pearance, nuclear pseudoinclusions, the presence of ovoid 
cell nuclei, and psammoma bodies. Additionally, papillary 
carcinomas with classical-type features revealed character-
istic papillary architecture, pure or admixed with follicles 
in variable proportion. 
Immunohistochemistry. Archival paraffin tissue blocks were 
used to obtain 4 μm-thick sections that were transferred onto 
adhesive slides, deparaffinized in xylene, rehydrated in grad-
ed ethanol, and washed in water and phosphate-buffered 
saline (PBS). Slides were immunostained in an autostainer 
(Dako, Glostrup, Denmark) with monoclonal antibodies 
directed against the CK19 antigen (CK19, clone RCK108, 
Dako). The IHC technique was performed using the EnVi-
sion FLEX method (Dako), using the chromogen 5’,5’-di-
aminobenzidine (DAB) as a substrate. Finally, all slides 
were counterstained with Mayer’s hematoxylin (Dako). 
Appropriate positive and negative controls were prepared. 
The positive control for CK19 was skin (epidermis). The 
negative controls were carried out by replacing the primary 
antibody with PBS. A positive membranous expression with 
or without cytoplasmic staining of neoplastic cells qualified 
the case as positive for CK19.
All immunostainings were evaluated by two patholo-
gists using an Olympus BX-41 light microscope (Olympus, 
Tokyo, Japan), and the immunohistochemical reaction was 
scored using the so-called Allred score, which is the sum of 
the percentage score (percentage of immunopositive cells) 
and the staining intensity score (labeling intensity) [32]. 
Table 1. Demographic, clinical, and histopathological cha-
racteristics of patients with the classical subtype of papillary 
thyroid carcinoma (CSPTC)
Parameter Average ± SD or number (%)
Gender
Females 135 (90.6%)
Males 14 (9.4%)
Age (years)
All patients 52.3 ± 15.0
Female 52.1 ± 15.1
Male 55.5 ± 15.3
Age
All patients:
< 45 44 (29.5)
≥ 45 105 (70.5)
Female:
< 45 41 (30.4)
≥ 45 94 (69.6)
Male: 
< 45 3 (21.4)
≥ 45 11 (78.6)
Unifocal or multifocal PTC
Unifocal 141 (94.6)
Multifocal 8 (5.4)
Recurrence
Nonrecurrence 136 (91.3)
Recurrence 13 (8.7)
pTNM*
I 113 (75.8)
II 19 (12.8)
III 15 (10.1)
IV 2 (1.3)
pT
pT1a 52 (34.9)
pT1b 63 (42.3)
pT2 26 (17.4)
pT3 7 (4.7)
pT4 1 (0.7)
pN
pN0 125 (83.9)
pN1a 21 (14.1)
pN1b 3 (2.0)
M
pM0 148 (99.3)
pM1 1 (0.7)
Cytokeratin 19 expression 
Positive 142 (95.3)
Negative 7 (4.7)
*TNM classification according to pTNM staging [43].
A proportional score was assigned representing the estimat-
ed proportion of positive, immunoreactive tumor cells (0: 
none; 1: < 1/100; 2: > 1/100 but less than 1/10; 3: > 1/10 but 
less than 1/3; 4: > 1/3 but less than 2/3; 5: > 2/3). Average 
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estimated intensity of immunostaining was assigned an in-
tensity score (0: none; 1: weak; 2: intermediate; 3: strong). 
The proportional score [PS] and the intensity score [IS] 
were added to obtain total score [TS], ranging from 0 to 8. 
Sections with Allred scores of ≤ 2 were considered negative 
while those with Allred scores ≥ 3 were taken as positive.
Statistical analysis. All the statistical analysis was performed 
using Prism 5.0 (GraphPad, CA, USA) and Statistica 10 
(StatSoft Inc., Tulsa, OK, USA) software. The type of vari-
able distribution was determined using the Shapiro-Wilk 
normality test. To analyze the correlations of CK19 expres-
sion with the clinical and pathological data chi-square test, 
the Fisher exact test or the Spearman correlation test were 
used. The Mann-Whitney U-test and the Kruskal-Wallis test 
were used to compare the differences in CK19 expression 
according to Allred score. To analyze the Recurrence Free 
Survival period, the Kaplan-Meyer curve was obtained and 
the Mantel-Cox test was employed. Univariate and multi-
variate Cox analysis of survival was also performed. The 
results were considered statistically significant at p < 0.05. 
Results
The immunoreactivity of CK19 was noted in the cy-
toplasm and cell membranes of the papillary thyroid 
carcinoma cells (Figure 1). The demographic, clinical, 
and histopathological characteristics of the patients with 
CSPTC are presented in Table 1. One hundred and for-
ty-nine patients — of which 135 (90.6%) were females 
and 14 (9.4%) males — with a diagnosis of CSPTC were 
evaluated. The mean age was 52.3 years (± 15.0). The 
majority of patients had unifocal PTC (141 individuals, 
94.6%). Thirteen (8.7%) individuals presented recur-
rence of PTC in the follow-up period. The majority of 
patients at the time of diagnosis and treatment were 
in the earlier stages of the disease (pT1a or pT1b: 115 
patients, 77.2%); however, there were 7 (4.7%) and 
1 (0.7%) patients in stages pT3 and pT4, respectively. 
In the case of 24 (16.1%) and 1 (0.7%) individuals, 
lymph node and distant metastases, respectively, were 
observed. In 95.3% of examined CSTPTC cases, we ob-
served positive cytoplasmic staining of CK19 (Table 1). 
As shown in Table 2, the intensity of CK19 immu-
nostaining did not correlate with age (p = 0.570), gen-
der (p = 0.157), tumor focality (p = 0.511), disease stage 
at the time of diagnosis (p = 0.423), tumor size (pT; 
p = 0.692), lymph node involvement (pN; p = 0.196), 
or distant metastases (pM; p = 1.0). However, we found 
significantly higher expression of CK19 in patients who 
survived the entire follow-up period without recurrence 
(p = 0.015, Mann-Whitney test; Figure 2). In addition, 
Figure 1. CK19 expression in papillary thyroid carcinoma. Immunohistochemical staining was performed as described  
in Material and methods. Immunoreactivity was observed in the cytoplasm and cell membrane of carcinoma cells.  
A, B. Weak cytoplasmic expression; C, D. Strong cytoplasmic expression. Magnification ×400.
A B
C D
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Recurrence Free Survival analysis showed that patients 
with negative [7 (4.7%)] or low expression of CK19 
lived without recurrence significantly shorter than 
did patients with moderate or high CK19 expression 
(p < 0.05, Mantel-Cox test; Figure 3). Univariate and 
multivariate Cox analysis of survival shows Table 3.
Discussion
It is estimated that about 20% of patients with PTC at 
the time of diagnosis and treatment had lymph node 
metastases, and the same number of patients had 
a more aggressive disease course, with early recurrence 
of the tumor [33]. Because of this, very accurate mark-
ers, which can predict the worse prognosis, even with 
early treatment, are crucial for clinical management. 
Some authors have suggested that conventional, 
histopathological, and immunohistochemical dia-
gnostic methods play an important role in providing 
a definitive diagnosis and therapeutic guidance [20, 
34]. Some biomarkers, such as thyroperoxidase, cyto-
keratins, galectin-3, and Hector Battifora mesothelial 
Table 2. Intensity of cytokeratin-19 (CK19) expression in relation to the clinical and pathological parameters in patients 
with the classical subtype of PTC (n = 149)
Parameter CK19 expression positive/negative p-value1 CK19 intensity median (min, max) p-value2
Gender
Female 128/7 0.494 5 (0, 8) 0.157
Male 14/0 3 (1, 7)
Age
Total group:
< 45 41/3 0.340 4 (0, 8) 0.570
≥ 45 101/4 2+ (0, 8)
Female:
< 45 38/3 0.460 2 (0, 3) 0.523
≥ 45 90/4 2 (0, 3)
Male:
< 45 3/0 1.000 2 (1, 3) 0.437
≥ 45 11/0 1 (1, 3)
Unifocal or multifocal PTC
Unifocal 135/6 0.326 5 (0, 8) 0.511
Multifocal 7/1 6.5 (0, 8)
Recurrence
Nonrecurrence 129/7 0.521 5 (0, 8) 0.015*
Recurrence 13/0 2 (1, 8)
pTNM
I 106/7 0.505 5 (0, 8) 0.423
II 19/0 5 (2, 8)
III 15/0 4 (1, 8)
IV 2/0 1.5 (1, 2)
pT
pT1a 51/1 0.591 5 (0, 8) 0.692
pT1b 58/5 4 (0, 8)
pT2 25/1 5.5 (0, 8)
pT3 7/0 5 (1, 8)
pT4 1/0 2 (2)
pN
pN0 118/7 0.494 2+ (0, 3+) 0.196
pN1a 21/0 1+ (1+, 3+)
pN1b 3/0 1+ (1+, 1+)
pM
pM0 141/7 0.953 5 (0, 8) 1.000
pM1 1/0 1 (1)
p-value1 — chi-square test with exact Fisher test; p-value2 — Mann-Whitney or Kruskal-Wallis tests; PTC — papillary thyroid carcinoma; *statisti-
cally significant difference.
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Nearly sixty years ago, Bjorklund proposed CK19 
as a possible marker for epithelial tumors [37]; fifty 
years later, Uenishi et al. [21] showed that the inci-
dence of extrahepatic disease, such as lymph node 
metastases, in patients with hepatocellular carcinomas 
was significantly higher in those with positive expres-
sion of CK19. They concluded that positive CK19 ex-
pression was a predictor of early postoperative recur-
rence, due to increased invasiveness. Song et al. [38] 
clearly established that the immunohistochemical 
expression of CK19 in PTC allowed nonmalignant 
thyroid lesions to be distinguished from PTC, which 
demonstrated diffuse and strong cytoplasmic CK19 
staining; however, they did not describe any correla-
tion between CK19 cytoplasmic staining and postop-
erative course. Very similar results were obtained by 
Lam et al. [39]. In their study of 153 thyroid carcinoma 
cases, strong, diffuse staining of CK19 was observed in 
more than 80% of PTC cases, while focal staining was 
seen in more than 60% of follicular thyroid carcino-
mas. In agreement with the previous reports [38, 39], 
we observed positive CK19 expression in almost all 
(95.3%) patients with CSTPTC. In 47 (31.5%), the 
staining was weak; in 41 (27.5%) medium; and in 
54 (36.3%) strong. Only in 7 (4.7%) CSTPTC cases 
did we see no CK19 expression. 
Calangiu et al. [40] provided some new informa-
tion on the usefulness of CK19 in differentiating the 
classical and follicular papillary carcinomas and the 
tall-cell variant of PTC. They observed higher CK19 
immunostaining in the classical and follicular types; 
however, they did not analyze the correlation of CK19 
immunostaining with the postsurgical course of the 
patients. Liu et al. [41] investigated the correlation 
between CK19 expression and the aggressive behavior 
of PTC. They showed that the expression of CK19 
did not have any association with capsular invasion 
or lymph node metastases. They also did not consider 
the postoperative course of their patients in terms of 
CK19 expression [41]. 
In our study, we found the significant correlation 
of the lower intensity of CK19 expression with a worse 
prognosis of CSTPTC postsurgical course. In our pa-
tients, thus was demonstrated as early recurrence. The 
higher expression of CK19 was correlated with better 
postsurgical course — that is, the absence of recurrence. 
Kosacka et al. [42] presented very similar observations; 
their study was also performed in the Silesian region, 
but concerned malignancies of other organs. As in the 
present study, they showed that higher expression of 
CK19 in non-small cell lung carcinoma correlated with 
better prognosis in patients after surgical treatment.
The reasons for the discrepancies in CK19 ex-
pression and postsurgical course of PTC are not 
Figure 2. Immunoexpression of cytokeratin 19 (CK19) in 
the recurrent and nonrecurrent group of papillary thyroid 
carcinoma patients. *p = 0.0148 (Mann-Whitney test).
Figure 3. Survival analysis for patients with the classical 
subtype of papillary thyroid carcinoma (CSPTC) with 
CK19 cytoplasmic expression in carcinoma cells. Patients 
with higher CK19 expression in carcinoma cells lived 
without recurrence of the disease significantly longer than 
did patients with lower expression of CK19. * p < 0.05, 
Mantel-Cox test.
epitope-1, have some significance in differentiating 
thyroid carcinomas and have been widely described 
[20, 35, 36]. However, their value as prognostic fac-
tors of the aggressive course of PTC has not been 
clearly established [2, 20, 34–36]. Knowledge of high 
aggressiveness in PTC and the high probability of its 
early recurrence — even after early primary surgical 
treatment — may improve the effectiveness of further 
treatment. 
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clear. Possible explanations include geographical 
differences; however, a more reasonable explanation 
could be related to the pathogenic mechanism in thy-
roid carcinogenesis: the tumor cells express CK19 at 
the beginning of the malignant process, but perhaps 
they lose these proteins during the progression of 
carcinogenetic process. 
In our study, the intensity of CK19 expression did 
not correlate with age, gender, disease stage, primary 
tumor dimension, multifocality, or lymph node me-
tastases. However, we confirmed the hypothesis that 
there was a correlation between the intensity of CK19 
expression in immunohistochemical staining and the 
postsurgical course of CSTPTC. Our compositional 
data analysis offers a novel analytic approach for immu-
nohistochemical studies, providing greater insight into 
the differences in intensity of staining patterns between 
papillary thyroid carcinomas. CK19 was expressed 
by tumor cells in almost all patients with CSPTC in 
the Silesian region. The higher expression of CK19 
Table 3. Univariate and multivariate Cox analysis of survival
Characteristics Univariate Cox analysis Multivariate Cox analysis
Overall survival Overall survival
HR 95% CI P-value HR 95% CI P-value
CK19 expression
0.139 0.038–0.511 0.0293 0.245 0.053–1.130 0.071Positive
Negative 
Age
0.648 0.209–1.959 0.435< 45
≥ 45
Gender
1.794 0.396–8.128 0.448Female
Male
Unifocal or multifocal PTC
1.452
0.188–
11.170
0.720Unifocal
Multifocal
pTNM
3.636 2.120) 6.238 < 0.0001 1.743 0.884–3.436 0.108
I
II
III
IV
pT
2.576 1.537–4.317 0.0003 0.507 0.897–2.534 0.120
pT1a
pT1b
pT2
pT3
pT4
pN
10.763
4.897–
23.657
< 0.0001 4.244
1.438–
12.518
0.0088
pN0
pN1a
pN1b
pM
18.295
2.289–
146.225
0.0061 2.460
0.210–
28.774
0.473pM0
pM1
Bold — statistically significant values; CI — confidence interval; PTC — papillary thyroid carcinoma.
correlated with favorable postoperative course with 
no recurrence. We suggest that the low expression of 
CK19 could be a possible indicative factor for recur-
rence. However, our study also shows great differences 
between the numbers of patients diagnosed and treated 
in the initial stages of the disease (132 (88.59%) of 
patients in stage I or II;) and in the advanced stages, 
with 15 (10.06%) and 2 (1.34%) individuals, respective-
ly, in stages III and IV. The same situation concerns 
the recurrence and nonrecurrence subgroups, which 
contained 136 (91.27%) and 13 (8.72%) patients, re-
spectively. This may affect the statistical analysis. For 
this reason, our results should be treated as preliminary, 
and ought to be verified by further studies on larger, 
more homogenous groups of patients.
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